July 7, 2020 – MedAlliance announced enrollment of the first patient in its study of Selution SLR 0.014 drug-eluting balloon (DEB) for the treatment of in-stent restenosis (ISR). This is the first DEB accepted by the FDA for its breakthrough program. The Selution SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES).
